BITI Biotie Therapies Corp. (MM)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April, 2016

 

 

Commission File Number: 001-37423

 

Biotie Therapies Oyj  

(Exact name of registrant as specified in its charter)

 

Biotie Therapies Corp.  

(Translation of registrant’s name into English)

 

Joukahaisenkatu 6, FI-20520

Turku, Finland

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

☒

Form 40-F

☐

 

  Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

 

Yes

☐

No

☒

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

 

Yes

☐

No

☒

 

   

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

			BIOTIE THERAPIES CORP.
			By:	/s/ David Cook
				Name:	David Cook
				Title:	Chief Financial Officer

 

Date: April 20, 2016

 

 

EXHIBIT INDEX

 

Exhibit Number	Description
99.1	Stock Exchange Release dated April 20, 2016 (4:30 p.m. EET):  Disclosure under Chapter 9, Section 5 of the Finnish Securities Markets Act